Cargando…

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

BACKGROUND: Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koyama, N., Iwase, O., Nakashima, E., Kishida, K., Kondo, T., Watanabe, Y., Takahashi, H., Umebayashi, Y., Ogawa, Y., Miura, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789617/ https://www.ncbi.nlm.nih.gov/pubmed/29378571 http://dx.doi.org/10.1186/s12890-018-0592-x

Ejemplares similares

Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)

Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis
por: Schneider, Thomas-Michael, et al.
Publicado: (2017)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer
por: Kasi, Arbab Furquan Ud din, et al.
Publicado: (2023)

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
por: Nakamura, Kenji, et al.
Publicado: (2018)

An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis
por: Vansteenkiste, Johan
Publicado: (2017)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
por: Fukasawa, Yoko, et al.
Publicado: (2017)

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy
por: Noda‐Narita, Shoko, et al.
Publicado: (2022)

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis
por: Yamaguchi, Teppei, et al.
Publicado: (2021)

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights
por: Foukas, Periklis G., et al.
Publicado: (2018)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023)

Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report
por: Mendiola, Vincent Louie, et al.
Publicado: (2019)

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
por: Li, Hong, et al.
Publicado: (2017)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
por: Souza, Ive L., et al.
Publicado: (2020)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma
por: Liao, Ji-Ping, et al.
Publicado: (2017)

Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023)

Risk exposures in early life and incidence of early-onset colorectal cancer across countries
por: Wang, Z Y, et al.
Publicado: (2023)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021)

New-onset insulin-dependent diabetes due to nivolumab
por: Zaied, Ali A, et al.
Publicado: (2018)

Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy
por: Lee, Senhong, et al.
Publicado: (2018)

Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options
por: Daetwyler, Eveline, et al.
Publicado: (2023)

Gemcitabine induced pneumonitis: a case report and review of literature
por: Thalambedu, Nishanth, et al.
Publicado: (2020)

Development of Arthritis as the Initial Involvement in Adult-Onset Cutaneous Polyarteritis Nodosa: Two Cases and Literature Review
por: Takamatsu, Ryota, et al.
Publicado: (2020)

Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and outcomes
por: Kang, Jieun, et al.
Publicado: (2021)

Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series
por: Kimura, Hideharu, et al.
Publicado: (2021)

Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report
por: Ueno, Shohei, et al.
Publicado: (2021)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Further Notes on the Incidence of Pneumonic Plague Cases in Gaya (Bihar)
por: Seal, S. C., et al.
Publicado: (1949)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

Tumor invasion in the central airway is a risk factor for early‐onset checkpoint inhibitor pneumonitis in patients with non‐small cell lung cancer
por: Moda, Mitsuhiro, et al.
Publicado: (2020)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
por: Kanda, S., et al.
Publicado: (2016)

Nivolumab in the treatment of malignant melanoma: review of the literature
por: Mashima, Emi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ep7ioo719hpigl9kmf5p302c1j